Ensartinib outperforms crizotinib as a treatment for patients with ALK-positive NSCLC who were naïve to ALK-targeted therapy
Ensartinib outperforms crizotinib as a treatment
Improved median PFS for patients with late-stage non-squamous NSCLC treated with first-line sintilimab plus conventional chemotherapy regimen
Improved median PFS for patients with late-stage
Interview: “We need chemotherapy when rapid responses are required”
Interview: “We need chemotherapy when rapid resp
